The efficacy of nonsteroidal anti-inflammatories in the prevention of heterotopic ossification following elbow trauma surgery

Kieran Bochat, MBBS*, Andrew C. Mattin, MBBS, FRACS, Brendan J. Ricciardo, MBBS, FRACS

Department of Orthopaedic Surgery, Fiona Stanley Hospital, Murdoch, Western Australia

**A R T I C L E   I N F O**

Keywords: Elbow
Trauma
Heterotopic ossification
Nonsteroidal anti-inflammatories
Prophylaxis
Prevention

**Level of Evidence:** Level III; Retrospective Cohort Comparison; Treatment Study

**Background:** Heterotopic ossification (HO) is common following surgery for elbow trauma and can have a significant impact on elbow function. The use of nonsteroidal anti-inflammatories (NSAIDs) for HO prophylaxis following total hip arthroplasty is well described, with the gold standard of indomethacin 25 mg tid for 6 weeks widely accepted.7–10 However, evidence for NSAID efficacy in elbow trauma patients is lacking.7–8 Sun et al found that a course of celecoxib was associated with lower rates of HO recurrence after open arthrolysis for elbow stiffness secondary to HO.5 We believe this to be the first cohort study investigating the effect of NSAIDs on the incidence of HO about the elbow following surgery for trauma.

**Materials and methods**

A search of the Fiona Stanley Hospital, Perth, Western Australia theater database for procedures undertaken for elbow trauma between January 2015 and June 2020 was performed. Operation reports were reviewed on a case by case basis to identify the exact surgical procedure. Only procedures involving the elbow joint were included; specifically, intraarticular distal humerus

Institutional review board approval was not required for this retrospective study.

* Corresponding author: Kieran Bochat, MBBS, Department of Orthopaedic Surgery, Fiona Stanley Hospital, Robin Warren Drive, Murdoch WA 6150.

E-mail address: kieran.bochat@health.wa.gov.au (K. Bochat).

© 2021 The Authors. Published by Elsevier Inc. on behalf of American Shoulder and Elbow Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
fractures, proximal radius and ulna fractures, and elbow dislocations. Pediatric patients (<16 years of age) were excluded. One hundred and fifty-three operations were identified. Surgery was performed within 3 weeks of injury. Prescribed NSAIDs included celecoxib, ibuprofen, indomethacin, meloxicam, and naproxen. Course duration varied from 3 days to 6 weeks. Postoperative radiographs were reviewed for each case and notes were reviewed to determine the degree of HO according to the Hastings and Graham classification.\(^2\) Radiographic follow-up was variable between 1 and 37 months. Electronic patient records were reviewed to determine prescription of NSAIDs, biographical data, and complications. Sixty-nine patient records were incomplete, leaving 84 complete data sets for analysis by multimonial logistic regression.\(^6\)\(^,\)\(^14\)\(^,\)\(^15\) Six explanatory variables were fitted to the model to predict the incidence of HO with NSAID, gender, and mechanism as categorical variables, and age, body mass index (BMI), and American Society of Anesthesiologists (ASA) classification as continuous variables. Reference level was "no HO." The model had an accuracy of 80% and a kappa value of 0.375. Findings were statistically significant if the \(P\) value <.05.

Results

The overall incidence of HO in our cohort was low (34 of 153 patients; 22%). Seventy-eight patients received NSAIDs postoperatively, compared to 72 who did not receive any NSAID. The prescribing history of 3 patients was not able to be determined. The incidence of HO was similar in both groups (24% taking NSAIDs, and 21% in those not taking NSAIDs). There was no significant difference in the severity of HO between the 2 groups (see Table I). Ten of the 153 patients were specifically prescribed a prophylactic course of NSAIDs at the discretion of the treating surgeon. Within this group, 5 patients developed HO (50%) and 5 did not (50%).

The incidence of HO was similar across high and low energy injuries (23% vs. 22%, respectively). High energy injury was defined as a motor vehicle trauma, fall from a bicycle at speed, fall from >1.5 m. Low energy trauma was a fall from standing height or <1.5 m. HO was more common with increasing age, female gender, and increased BMI were predictive for higher incidence of HO. Risks of NSAID therapy appear low, with only 1.3% patients suffering a nonunion.

A multinomial logistic regression model was used to identify risk factors for HO formation. Six factors were identified: prescription of NSAIDs, age, gender, mechanism of injury, ASA, and BMI. This reduced the data set to 84 complete records, primarily because BMI data were missing for 65 patients. The model identified high energy mechanism of injury (\(P = .038\)) and increased BMI (\(P = .045\)) as being predictive for HO formation with an accuracy of 80% and kappa value of 0.375 (see Table V). Excluding BMI increased the number of complete data records to 145, although this model was much less accurate than the model including BMI suggesting that BMI plays a significant role in HO risk.

Complications were low within the cohort. Infection rate was 1.3% (2 patients) with both patients returning to theater for removal of metal. Only 1 patient suffered a fracture nonunion. This patient had been prescribed NSAIDs postoperatively, and returned to theater for removal of metal; no further operative procedure was undertaken. There were 4 other patients who had to return to the theater (total of 4.6% of the cohort): 2 for removal of metal for irritation, 1 for removal of over-stuffed radial head prosthesis, and 1 for arthroscopy for loose bodies causing mechanical symptoms.

#### Table I

| Characteristic | Total patients | Patients with HO | Incidence (%) |
|----------------|----------------|------------------|---------------|
| Prescribed NSAIDs | Yes | 78 | 19 | 24 |
| | No | 72 | 15 | 21 |
| Prophylactic course\(^1\) | No | 72 | 15 | 21 |
| | Yes | 78 | 19 | 24 |
| Age (yr) | 16-65 | 116 | 20 | 17 |
| | >65 | 37 | 14 | 38 |
| Gender | Male | 70 | 12 | 17 |
| | Female | 83 | 22 | 27 |
| Mechanism of injury | Low energy | 99 | 23 | 23 |
| | High energy | 49 | 11 | 22 |
| BMI | <18.5 | 0 | 0 | - |
| | 18.5-24.9 | 33 | 5 | 15 |
| | 25-29.9 | 29 | 5 | 17 |
| | 30-34.9 | 14 | 3 | 21 |
| | 35-40 | 7 | 2 | 29 |
| | >40 | 5 | 3 | 60 |
| ASA class | 1 | 76 | 14 | 18 |
| | 2 | 50 | 12 | 24 |
| | 3 | 26 | 8 | 31 |
| | 4 | 0 | 0 | - |
| | 5 | 0 | 0 | - |

\(\text{HO, heterotopic ossification; NSAIDs, nonsteroidal anti-inflammatories; BMI, body mass index; ASA, American Society of Anesthesiologists.}\)

\(^1\) Patients were prescribed a 4-6 week course of NSAIDs.

#### Table II

| Characteristic | NSAIDs (n = 78) | No NSAIDs (n = 72) | \(P\) value |
|----------------|-----------------|-------------------|------------|
| HO grade\(^2\) | 1 | 16 (21%) | 11 (15%) | .44 |
| | 2 | 3 (3.8%) | 4 (5.6%) | .696 |
| | 3 | 0 | 0 | - |

\(\text{HO, heterotopic ossification; NSAIDs, nonsteroidal anti-inflammatories.}\)

\(^2\) Hastings and Graham classification.

Discussion

Our results challenge the notion that NSAIDs reduce the incidence of HO about the elbow after surgery for trauma. There was no appreciable difference in the rates of HO amongst those prescribed NSAIDs and those who were not. High energy mechanism of injury and increased BMI were predictive for higher incidence of HO. Risks of NSAID therapy appear low, with only 1.3% patients suffering a nonunion.

A weakness is the retrospective nature without randomization. There was a highly variable range of NSAIDs prescribed and duration of treatment. Amongst the 10 patients specifically prescribed prophylactic NSAIDs, the rate of HO was 50%. We believe there may have been a selection bias with injury severity and the clinical expertise of the treating surgeon leading to the prescription of prophylactic NSAIDs. BMI data were not available for 65 patients (42%), the presence of which may have strengthened the statistical analysis.

The variable and short radiographic follow-up of many patients may be perceived as a weakness. However, in our experience at our center, it is likely that patients experiencing problems in the longer term, including functional limitation due to HO, would have been referred back to the clinic for further assessment, and therefore captured by our analysis.
A prospective randomized study would appear low risk and give further information as to the effectiveness of NSAIDs for HO prophylaxis following elbow trauma surgery.

**Conclusion**

Although there is good evidence for indomethacin prophylaxis following surgery about the hip, NSAIDs did not reduce the occurrence of HO following surgery for elbow trauma. Patients with increased BMI and suffering high energy mechanism of trauma are more likely to develop HO. Risk of nonunion is low with NSAID therapy post elbow trauma surgery.

**Disclaimers:**

**Funding:** Funding was received from the Orthopaedic Research Foundation of Western Australia for the publication cost. No other funding was received for the production of this article.

**Conflicts of interest:** Dr Mattin has received institutional support from Depuy and Zimmer, though not in relation to the subject of this article. The other authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.

**Table III**

| NSAID       | No. of patients prescribed | No. of patients who developed HO | Rate of HO (%) | HO grade 1 | HO grade 2 |
|-------------|----------------------------|----------------------------------|----------------|------------|------------|
| Celecoxib   | 54                         | 11                               | 20             | 9 (17%)    | 2 (3.7%)   |
| Ibuprofen   | 18                         | 5                                | 28             | 5 (28%)    | -          |
| Indomethacin| 3                          | 1                                | 33             | 1 (33%)    | -          |
| Naproxen    | 2                          | 1                                | 50             | 1 (50%)    | -          |
| Meloxicam   | 1                          | 1                                | 100            | -          | 1 (100%)   |

HO, heterotopic ossification; NSAID, nonsteroidal anti-inflammatory.

**Table IV**

| NSAID       | No. of patients prescribed | No. of patients who developed HO | Rate of HO (%) | HO grade 1 | HO grade 2 |
|-------------|----------------------------|----------------------------------|----------------|------------|------------|
| Indomethacin| 3                          | 1                                | 33             | 1 (33%)    | -          |
| Celecoxib   | 4                          | 2                                | 50             | 2 (50%)    | -          |
| Naproxen    | 2                          | 1                                | 50             | 1 (50%)    | -          |
| Meloxicam   | 1                          | 1                                | 100            | -          | 1 (100%)   |
| Ibuprofen   | 0                          | -                                | -              | -          | -          |

HO, heterotopic ossification; NSAID, nonsteroidal anti-inflammatory.

**Table V**

| Characteristic     | Total patients | Patients with HO | Incidence (%) | P value |
|--------------------|----------------|------------------|---------------|---------|
| Prescribed NSAIDs  | 47             | 11               | 23            | .689    |
| Yes                | 37             | 7                | 19            |         |
| No                 | 4              | 1                | 25            |         |
| Prophylactic course* | 67             | 13               | 19            | .668    |
| Age (yr)           | 67             | 13               | 19            | .668    |
| >65                | 17             | 5                | 29            |         |
| Gender             | 39             | 8                | 21            | .997    |
| Male               | 45             | 10               | 22            |         |
| Female             | 39             | 8                | 21            | .997    |
| Mechanism of injury| 60             | 10               | 17            | .038    |
| Low energy         | 24             | 8                | 33            |         |
| High energy        | 24             | 8                | 33            |         |
| BMI                | <18.5          | -                | -             | .045    |
| 18.5-24.9          | 32             | 5                | 16            |         |
| 25-29.9            | 27             | 5                | 19            |         |
| 30-34.9            | 13             | 3                | 23            |         |
| 35-40              | 7              | 2                | 29            |         |
| 40+                | 5              | 3                | 60            |         |

ASA class

1 | 40 | 7 | 18 | .582 |
2 | 27 | 6 | 22 |
3 | 17 | 5 | 29 |
4 | 0  | - | -  |
5 | 0  | - | -  |

HO, heterotopic ossification; NSAIDs, nonsteroidal anti-inflammatories; BMI, body mass index; ASA, American Society of Anesthesiologists.

* Patients were prescribed a 4-6 week course of NSAIDs.

\[ P < .05 \]

Statistically significant by multinomial logistic regression, with NSAIDs, gender, and mechanism as categorical variables, and age, BMI, and ASA class as continuous variables; accuracy 80%, kappa 0.375.
Acknowledgments

We acknowledge the assistance offered by Richard Madayag, Clinical Applications Reporter, Theatre Management System, South Metropolitan Health Service of Western Australia and Glenn Boardman, Data Analyst, South Metropolitan Health Service of Western Australia.

References

1. Foruria AM, Augustin S, Morrey BF, Sanchez-Sotelo J. Heterotopic ossification after surgery for fractures and fracture-dislocations involving the proximal aspect of radius or ulna. J Bone Joint Surg Am 2013;95:e66. https://doi.org/10.2106/JBJS.K.01533.

2. Hamid N, Ashraf N, Bosse M, Connor PM, Kellam JF, Sims SH, et al. Radiation Therapy after heterotopic ossification prophylaxis acutely after elbow trauma. J Bone Joint Surg Am 2010;92:2032-8. https://doi.org/10.2106/JBJS.I.01435.

3. Hastings H, Graham TJ. The classification and treatment of heterotopic ossification about the elbow and forearm. Hand Clin 1994;10:417-37.

4. Hong CC, Nashi N, Hey HW, Chee YH, Murphy D. Clinically relevant heterotopic ossification after elbow fracture surgery: a risk factors study. Orthopaedics Traumatol Surg Res 2015;101:209-13. https://doi.org/10.1016/j.otsr.2014.10.021.

5. Juarez J, Wenke J, Rivera J. Treatments and preventative measures for trauma-induced heterotopic ossification: a review. Clin Transl Sci 2018;11:365-70. https://doi.org/10.1111/cts.12552.

6. Kuhn M. caret: Classification and Regression Training. R package version 6.0-85. Available at: https://CRAN.R-project.org/package=caret; 2020. Accessed 19 October 2020.

7. Lavernia CJ, Contreras JS, Villa JM, Rossi MD. Celecoxib and heterotopic bone formation after total hip arthroplasty. J Arthroplasty 2014;29:390-2. https://doi.org/10.1016/j.arth.2013.06.039.

8. Meyers C, Lisiecki J, Miller S, Levin A, Fayad L, Ding C, et al. Heterotopic ossification: a comprehensive review. JBM R Plus 2019;3:1-19. https://doi.org/10.1002/jbmr4.10172.

9. Murnaghan M, Li G, Marsh DR. Nonsteroidal anti-inflammatory drug-induced fracture non-union: an inhibition of angiogenesis? J Bone Joint Surg Am 2006;88:140-7. https://doi.org/10.2106/JBJS.F.00454.

10. Ritter MA, Sieber JM. Prophylactic indomethacin for the prevention of heterotopic bone formation following total hip arthroplasty. Clin Orthop Relat Res 1985;196:217-25.

11. Romano CL, Duci D, Romano D, Mazza M, Meani E. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty 2004;19:14-8. https://doi.org/10.1016/S0883-5403(03)00279-1.

12. Saudan M, Saudan P, Perneger T, Riand N, Keller A, Hoffmeyer P. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomized trial. J Bone Joint Surg Br 2007;89:155-9. https://doi.org/10.1302/0301-620X.89B2.17747.

13. Sun Y, Cai J, Li F, Liu S, Ruan H, Fan C. The efficacy of celecoxib in preventing heterotopic ossification recurrence after open arthrolysis for post-traumatic elbow stiffness in adults. J Shoulder Elbow Surg 2015;24:1735-40. https://doi.org/10.1016/j.jse.2015.07.006.

14. Venables WN, Ripley BD. Modern Applied Statistics with S. Fourth Edition. New York: Springer; 2002.

15. Wickham H. ggplot2: Elegant Graphics for data analysis. New York: Springer-Verlag; 2016.